ERBB2 and breast cancer: TBCRC-022 was a phase II trial that evaluated neratinib in combination with capecitabine, in two cohorts of patients (lapatinib-naïve or pre-treated-cohort 3A and 3B, respectively), with HER2-positive BC with CNS metastases.